Revvity's earnings call reflected strong operational execution and positive performance in diagnostics and software segments, alongside continued innovation and a robust share repurchase program. However, challenges persisted in the Life Sciences segment and the Chinese market, leading to a revised, lower organic growth outlook for the year.

Company Guidance

During Revvity's third-quarter 2024 earnings call, the company reported better-than-expected performance in several key financial metrics, including total revenue, adjusted operating margin, and adjusted EPS. The adjusted operating margin increased by 80 basis points to 28.3% due to productivity initiatives, while free cash flow reached $135 million, achieving a 100% conversion rate to adjusted net income. The company also returned over 100% of its cash flow to shareholders through buybacks and dividends. Looking ahead, Revvity anticipates fourth-quarter organic growth in the range of 3% to 5%, resulting in a full-year growth outlook of 0% to 1%, slightly below previous expectations. Despite challenges in the instrumentation market, particularly in China, the company remains optimistic about its future, raising its full-year adjusted EPS guidance to between $4.83 and $4.87.

Strong Operational Execution

Revvity's strong execution led to adjusted operating margins increasing by 80 basis points year-over-year to 28.3% in the quarter. Free cash flow was $135 million with 100% conversion to adjusted net income.

Positive Diagnostics and Software Performance

Diagnostics segment grew by 5% organically, with Immunodiagnostics and Reproductive Health businesses showing strong performance. Software business expected to grow in low double digits for the full year.

Innovation and Product Launches

Successful launch of Phenologic AI and Revvity transcribed AI service, enhancing diagnostics and screening capabilities. New genotyping solution launched in Europe for Alzheimer's disease risk assessment.

Aggressive Share Repurchase Program

Board approved a new $1 billion share repurchase authorization over the next 2 years, highlighting strong cash flow performance and balance sheet stability.

---

Revvity (RVTY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RVTY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 01, 2018	2018 (Q2)	- / 0.91	0.67	35.82% (+0.24)	―	―
Oct 31, 2018	2018 (Q3)	- / 0.90	0.73	23.29% (+0.17)	―	―
Jan 31, 2019	2018 (Q4)	- / 1.18	0.97	21.65% (+0.21)	―	―
Apr 25, 2019	2019 (Q1)	- / 0.69	0.63	9.52% (+0.06)	―	―
Jul 29, 2019	2019 (Q2)	- / 1.00	0.91	9.89% (+0.09)	―	―
Oct 30, 2019	2019 (Q3)	- / 1.06	0.9	17.78% (+0.16)	―	―
Jan 27, 2020	2019 (Q4)	- / 1.35	1.18	14.41% (+0.17)	―	―
May 05, 2020	2020 (Q1)	- / 0.67	0.69	-2.90% (-0.02)	―	―
Jul 28, 2020	2020 (Q2)	- / 1.57	1	57.00% (+0.57)	―	―
Oct 28, 2020	2020 (Q3)	- / 2.09	1.06	97.17% (+1.03)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

RVTY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2024	$120.97	$124.75	+3.12%
Jul 29, 2024	$115.01	$125.44	+9.07%
Apr 29, 2024	$101.33	$104.83	+3.45%
Feb 01, 2024	$106.91	$108.99	+1.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---